Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Celularity (CELU) over the last 6 years, with Q3 2025 value amounting to $3.5 million.

  • Celularity's Cash from Financing Activities rose 450253.16% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 3355.39%. This contributed to the annual value of $6.7 million for FY2024, which is 7218.81% down from last year.
  • According to the latest figures from Q3 2025, Celularity's Cash from Financing Activities is $3.5 million, which was up 450253.16% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Celularity's Cash from Financing Activities ranged from a high of $100.4 million in Q3 2021 and a low of -$4.8 million during Q1 2021
  • Over the past 5 years, Celularity's median Cash from Financing Activities value was $3.5 million (recorded in 2025), while the average stood at $13.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 21987.38% in 2021, then surged by 469285.71% in 2024.
  • Quarter analysis of 5 years shows Celularity's Cash from Financing Activities stood at -$1.0 million in 2021, then soared by 266.17% to $1.7 million in 2022, then tumbled by 100.83% to -$14000.0 in 2023, then skyrocketed by 4692.86% to $643000.0 in 2024, then soared by 440.9% to $3.5 million in 2025.
  • Its Cash from Financing Activities stands at $3.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $2.3 million for Q1 2025.